medigraphic.com
ISSN 0016-3813 (Print)

2008, Number 1

<< Back Next >>

Gac Med Mex 2008; 144 (1)

Obesidad, inflamación y diabetes

Miranda-Garduño LM, Reza-Albarrán A

Language: Spanish
References: 40
Page: 36-46
PDF size: 119.07 Kb.


ABSTRACT

Integration of metabolism and immunity in normal physiology is beneficial to maintain homeostasis. It can also become deleterious under conditions such as the immunosuppression observed among the malnourished. With the increase of excess weight and obesity, a new set of problems and complications has emerged at the intersection of metabolic activity and immunity. As examples of the latter we find obesity associated with inflammatory diseases, diabetes, fatty liver disease and atherosclerosis. Obesity is characterized by inflammation; there are common factors at the crossroads of inflammation and metabolic disease. Obesity is characterized by an inflammatory response and many inflammatory mediators exhibit expression patterns that interfere with insulin action. The high level of coordination of inflammatory and metabolic pathways is highlighted by the overlapping biology of macrophage and adipocite function observed in obesity. The intracellular signaling pathways activated by inflammatory and stress responses inhibit insulin signaling and the loss of inflammatory mediators prevents insulin resistance. In the absence of obesity, an infusion of inflammatory cytokines or lipids causes insulin resistance. Understanding the mechanisms leading from obesity to inflammation will have important implications to help reduce the morbidity and mortality associated with obesity bypreventing its association with inflammatory disorders.


REFERENCES

  1. Khovidhunkit W, Dunchateau PN, Medzihraszk KF, Moser AH, Naya-Vigne J, Shigenaga JK, et al. Effects of infecction and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host [review]. J Lipid Res 2004;45:1169–1196.

  2. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993;259:87-91.

  3. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 1995;95:2409-2415.

  4. Kern PA, Saghizadeh M, Ong JM, Bosch RJ, Deem R, Simsolo RB. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 1995;95:2111-2119.

  5. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 1997;389:610-614.

  6. Shmidt MI. Markers of inflammation and prediction of diabetes mellitus in adults (atherosclerosis risk in communities study): a cohort study. Lancet 1999;353:1649-1652

  7. Freeman DJ, Norrie J, Caslake MJ, Gaw A, Ford I, Lowe GD, et al. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 2002;51:1596- 1600.

  8. Pickup JC. Inflammation and activated innate immunity in the pathogenesis of type diabetes. Diabetes Care 2004;27:813-823.

  9. Dandona P, Aljada A, Bandyopadhay A. Inflamation: the link between insulin resistance, obesity and diabetes. Trends Immunol 2004;25:4-7.

  10. Lord GM, Matarese G, Howard JK, Baker RJ, Bloom SR, Lechler RI. Leptin modulates the T-cell immune response and reverses starvation-induced immunosupression. Nature 1998;394:897-901

  11. Fukuhara, A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005;307:426-430.

  12. Vilarrasa N, Vendrell J, Maravall J, Broch M, Estepa A, Megia A, et al. Distribution and determinants of adiponectin, resistin and ghrelin in a randomly selected healthy population. Clinical Endocrionology 2005;63:329-335.

  13. Steppan CM, Lazar MA. The current biology of resistin. J Intern Med 2004;255:439–447.

  14. Bouloumie A, Senegenés C, Portolan G, Galitzky J, Lafontan M. Adipocyte produces matrix metalloproteinases 2 and 9:involvement in adipose differentiation. Diabetes 2001;50:2080–2086.

  15. Charrière G, Cousin B, Arnaund E, André M, Bacou F, Pénicaud L, et al. Preadipocyte conversión to macrophage. Evidence of plasticity. J Biol Chem 2003;278:9850–9855.

  16. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003;112:1796–1808.

  17. White MF. The insulin signalling system and the IRS proteins. Diabetologia 1997;40(Suppl. 2):S2–S17.

  18. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibición of insulin receptor tyrosine kinase activity in TNFalpha- and obesity-induced insulin resistance. Science 1996;271:665–668.

  19. Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell 2000;103:239-252.

  20. Aguirre V, Werner ED, Giraud J, Lee YH, Shoelson SE, White MF. Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action. J Biol Chem 2002;277:1531-1537.

  21. Hirosumi J, Tuncman G, Chang L, Görgüm CZ, Uysal KT, Maeda K, et al. A central role for JNK in obesity and insulin resistance. Nature 2002;420:333–336.

  22. Paz K, Hemi R, LeRoith D, Karasik A, Elhanany E, Kanety H, et al. A molecular basis for insulin resistance. Elevated serine/threonine phosphorylation of IRS-1 and IRS-2 inhibits their binding to the juxtamembrane region of the insulina receptor and impairs their ability to undergo insulin-induced tyrosine phosphorylation. J Biol Chem 1997;272:29911-29918.

  23. Kaneto H, Nakatani Y, Miyatsuka T, Kawamori D, Matsuoka TA, Matsuhisa M, et al. Possible novel therapy for diabetes with cell-permeable JNKinhibitory peptide. Nat Med 2004;10:1128-1132.

  24. Yu C, Chen Y, Cline GW, Zhang D, Zong H, Wang Y. Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)- associated phosphatidylinositol 3-kinase activity in muscle. J Biol Chem 2002;277:50230-50236.

  25. Brownlee M. Banting Lecture 2004. The Pathobiology of Diabetic Complications. A Unifying Mechanism. Diabetes 2005;54:1615-1625.

  26. Hundal RS, Petersen KF, Mayerson AB, Randhawa PS, Inzucchi S, Shoelson SE. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest 2002;109:1321-1326.

  27. Perseghin, G, Petersen K, Shulman GI. Cellular mechanism of insulin resistance: potential links with inflammation. Int J Obes Relat Metab Disord 2003;27(Suppl 3):S6-S11.

  28. Rui L, Yuan M, Frantz D, Shoelson S, White MF. SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2. J Biol Chem 2002;277:42394-42398.

  29. Mooney, RA, Senn J, Cameron S, Inamdar N, Boivin LM, Shang Y, et al. Suppressors of cytokine signaling-1 and -6 associate with and inhibit the insulin receptor. A potential mechanism for cytokine-mediated insulin resistance. J Biol Chem 2001;276:25889-25893.

  30. Shimabukuro M, Koyama K, Lee Y, Unger RH. Role of nitric oxide in obesityinduced beta cell disease. J Clin Invest 1997;100:290-295

  31. Perreault M, Marette A. Targeted disruption of inducible nitric oxide synthase protects against obesity-linked insulin resistance in muscle. Nat Med 2001;7:1138-1143+

  32. Joseph SB, Castrillo A, Laffitte BA, Mangelsdorf DJ, Tontonoz P. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat Med 2003;9:213-219.

  33. Seo JB. Activated liver X receptors stimulate adipocyte differentiation through induction of peroxisome proliferator-activated receptor gamma expression. Mol Cell Biol 2004;24:3430-3444.

  34. Lee C, Plutzky J. Liver X Receptor Activation and high-density lipoproteína biology. A reversal of fortune? Circulation 2006;113:5-8.

  35. Jiang C, Ting AT, Seed B. PPARgamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998;391:82-86.

  36. Özcan U, Cao Q, Yilmaz E, Lee AH, Iwakoshi NN, Özdelen E, et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 2004;306:457-461.

  37. Nakatani Y, Kaneto H, Kawamori D, Yoshiuchi K, Hatazaki M, Matsuoka T, et al. Involvement of endoplasmic reticulum stress in insulin resistance and diabetes. J Biol Chem 2005;280:847-851.

  38. Ozawa K, Miyazaki M, Natsuhisa M, Takano K, Nakatani Y, Hatzaki M, et al. The endoplasmic reticulum chaperone improves insulin resistance in type 2 diabetes. Diabetes 2005;54:657-663.

  39. Lin Y, Chen Y, Cline GW, Zhang D, Zong H, Wang Y, et al. The hyperglycemia- induced inflammatory response in adipocytes: the role of reactive oxygen species. J Biol Chem 2005;280:4617-4626.

  40. Lowell BB, Shulman GI. Mitochondrial dysfunction and type 2 diabetes. Science 2005;307:384-387.




2020     |     www.medigraphic.com